Eliquis receives ‘positive opinion’ from EMA
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended an addition to the current Summary of Product Characteristics (SmPC) and stated that ‘Patients can stay on apixaban while being cardioverted.’
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: AMcculloch Tags: Cardiovascular medicine apixaban ARISTOTLE Eliquis Latest News non-valvular atrial fibrillation stroke systemic embolism Source Type: news
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Drugs & Pharmacology | European Medicines Agency (EMA) | Heart | Stroke